ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1741

The Occurrence and Phenotype of Autoreactive T Cells in the At-Risk Phase of Rheumatoid Arthritis

Sara Turcinov1, Charlotte de Vries2, Ravi Kumar Sharma2, Christina Gerstner2, Bruno Raposo2, Anatoly Dubnovitsky2, William Kwok3, Karine Chemin2, Vivianne Malmström4 and Aase Hensvold5, 1Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet. Theme of Inflammation and Ageing, Medical Unit Gastro, Derma, Rheuma, Karolinska University Hospital, Stockholm, Sweden, 2Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 3Benaroya Research Institute at Virginia Mason, Seattle, WA, 4Karolinska Institutet, Stockholm, Sweden, 5Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet. Center for Rheumatology, Academic Specialist Center, Stockholm, Sweden

Meeting: ACR Convergence 2023

Keywords: Anti-CCP, autoantigens, rheumatoid arthritis, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1734–1775) RA – Etiology and Pathogenesis Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: CD4+ T cells recognizing citrullinated epitopes are present in peripheral blood of anti-citrulline protein antibody (ACPA) positive rheumatoid arthritis (RA) patients at time of diagnosis and during the disease course. However, it has not priorly been known if these rare cells also can be found preceding disease onset. The aim of this study was thus to investigate the presence of such autoreactive CD4+ T cells, in the at-risk phase of RA, in combination with deep T cell phenotyping.

Methods: Twenty individuals from the Karolinska Risk-RA cohort carrying the genetic risk allele, HLA-DRB1*04:01, were included in the study. At baseline, all individuals had musculoskeletal symptoms, concomitant anti-CCP-positivity, but no clinical or ultrasound signs of synovitis. Ten of these individuals progressed to arthritis (over a median period of 13 months following inclusion) and were matched to individuals that had not progressed during a median follow-up period of 53 months. Peripheral blood mononuclear cells (PBMC), from up to three sample timepoints during one year of risk phase, were assessed using HLA-class II tetramers with twelve different citrullinated candidate autoantigens (originating from tenascin-C, α-enolase, fibrinogen-β, vimentin and cartilage intermediate layer protein) and a viral influenza peptide as positive control, combined with multiparameter phenotyping using a 20-color spectral flow-cytometry panel.

Results: Overall, the baseline CD4+ phenotype was similar in individuals who progressed to arthritis and those who did not when studying markers associated with Th1, Th17, T-peripheral helper and T-regulatory cells as well as with cell activation. The memory T cell compartment was predominantly of effector memory phenotype. When looking at antigen specific T cells, all individuals had similar levels of influenza specific CD4+ T cells irrespectively of disease progression status. CD4+ T cells recognizing pools of citrullinated antigens were also present in both groups but at significantly higher frequency in the non-progressors, particularly those with reactivity towards citrullinated fibrinogen-β/vimentin. Within the arthritis progressor group, CD4+ T cells specific for citrullinated tenascin-C were the most frequently observed, with their frequencies diminishing during follow-up time points leading up to arthritis onset. These cit-tenascin-C reactive CD4+ T cells displayed phenotypes of both activation and regulatory function.

Conclusion: Autoreactive CD4+ T cells recognizing citrullinated antigens are present in the circulation before disease onset in ACPA-positive individuals with arthralgia carrying HLA-DRB1*04:01. Lower frequency of circulating citrulline specific cells in arthritis progressor individuals may suggest an ongoing homing of these cells to the joints.


Disclosures: S. Turcinov: None; C. de Vries: None; R. Kumar Sharma: None; C. Gerstner: None; B. Raposo: None; A. Dubnovitsky: None; W. Kwok: None; K. Chemin: Janssen, 5; V. Malmström: Eli Lilly, 1, Janssen, 5, ONO, 1, Pfizer, 5; A. Hensvold: None.

To cite this abstract in AMA style:

Turcinov S, de Vries C, Kumar Sharma R, Gerstner C, Raposo B, Dubnovitsky A, Kwok W, Chemin K, Malmström V, Hensvold A. The Occurrence and Phenotype of Autoreactive T Cells in the At-Risk Phase of Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/the-occurrence-and-phenotype-of-autoreactive-t-cells-in-the-at-risk-phase-of-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-occurrence-and-phenotype-of-autoreactive-t-cells-in-the-at-risk-phase-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology